These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 4611465

  • 1. Piribedil, a dopamine agonist, in Parkinson's disease.
    Sweet RD, Wasterlain CG, McDowell FH.
    Clin Pharmacol Ther; 1974 Dec; 16(6):1077-82. PubMed ID: 4611465
    [No Abstract] [Full Text] [Related]

  • 2. Proceedings: Effects of piribedil (ET 495)--a dopaminergic receptor stimulating agent in Parkinson's disease.
    Lieberman A, Le Brun Y, Zolfaghari M.
    Psychopharmacol Bull; 1974 Jul; 10(3):42-3. PubMed ID: 4419369
    [No Abstract] [Full Text] [Related]

  • 3. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL, Chalmers RJ, Johnson RH.
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [Abstract] [Full Text] [Related]

  • 4. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M, Sciannandrone R, Fieschi C, De Simone G.
    Riv Patol Nerv Ment; 1975 Jan; 96(2):103-10. PubMed ID: 778998
    [Abstract] [Full Text] [Related]

  • 5. Piribedil in Parkinson's syndrome: a clinical study.
    Engel J, Granerus AK, Svanborg A.
    Eur J Clin Pharmacol; 1975 Apr 04; 8(3-4):223-6. PubMed ID: 183960
    [Abstract] [Full Text] [Related]

  • 6. Parkinson disease treated with a suspected dopamine receptor agonist.
    Chase TN, Woods AC, Glaubiger GA.
    Arch Neurol; 1974 May 04; 30(5):383-6. PubMed ID: 4821783
    [No Abstract] [Full Text] [Related]

  • 7. Studies on piribedil in Parkinsonism.
    Lieberman AN, Shopsin B, Brun YL, Boal D, Zolfaghari M.
    Adv Neurol; 1975 May 04; 9():399-407. PubMed ID: 125032
    [No Abstract] [Full Text] [Related]

  • 8. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK, Sonninen V, Marttila R.
    Adv Neurol; 1975 May 04; 9():383-92. PubMed ID: 1096575
    [Abstract] [Full Text] [Related]

  • 9. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J, Chanelet J, Truelle JL, Bastard J.
    Adv Neurol; 1975 May 04; 9():409-13. PubMed ID: 1096577
    [No Abstract] [Full Text] [Related]

  • 10. [Long-term medical treatment of acute cerebrovascular disease sequelae (comparison papaverine-piribedil].
    Piccinelli A, Neri G, Agnoli A.
    Minerva Med; 1974 Nov 10; 65(80):4199-213. PubMed ID: 4610451
    [No Abstract] [Full Text] [Related]

  • 11. Proceedings: Clinical studies of dopaminergic mechanisms.
    Chase TN.
    Psychopharmacol Bull; 1974 Jul 10; 10(3):43-4. PubMed ID: 4419336
    [No Abstract] [Full Text] [Related]

  • 12. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD.
    Neurology; 1970 Dec 10; 20(12):Suppl:6-13. PubMed ID: 4921587
    [No Abstract] [Full Text] [Related]

  • 13. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
    Sweet RD, Wasterlain C, McDowell FH.
    Trans Am Neurol Assoc; 1974 Dec 10; 99():258-60. PubMed ID: 4463553
    [No Abstract] [Full Text] [Related]

  • 14. Amantadine for Parkinson's disease.
    Mann DC, Pearce LA, Waterbury LD.
    Neurology; 1971 Sep 10; 21(9):958-62. PubMed ID: 4936828
    [No Abstract] [Full Text] [Related]

  • 15. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G, Castaigne P, Lhermitte F, Beck H, Guillard A, Marteau R, Pepin B, Rondot P, Raphy B.
    Rev Neurol (Paris); 1970 Feb 10; 122(2):89-102. PubMed ID: 4931719
    [No Abstract] [Full Text] [Related]

  • 16. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P, Bathien N, Dumas JL.
    Adv Neurol; 1975 Feb 10; 9():373-81. PubMed ID: 1096574
    [No Abstract] [Full Text] [Related]

  • 17. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL, Chanelet J, Bastard J, Six P, Emile J.
    Nouv Presse Med; 1977 Oct 08; 6(33):2987-90. PubMed ID: 22844
    [Abstract] [Full Text] [Related]

  • 18. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
    Lieberman A, Le Brun Y, Boal D, Zolfaghari M.
    Adv Biochem Psychopharmacol; 1974 Oct 08; 12(0):415-25. PubMed ID: 4425258
    [No Abstract] [Full Text] [Related]

  • 19. A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
    Mindham RH, Lamb P, Bradley R.
    Br J Psychiatry; 1977 Jun 08; 130():581-5. PubMed ID: 326325
    [Abstract] [Full Text] [Related]

  • 20. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
    Pilipovich AA, Golubev VL.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017 Jun 08; 117(6):83-90. PubMed ID: 28745677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.